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Nanoparticles are the only materials small enough to target cells in the body,
and therefore are crucial to targeted drug delivery. Issues with the synthesis,
consistency, and bioactivity of these molecules are still being addressed, but base
on current proof of concept studies there is a reason to believe that the ‘holy grail’
of targeted drug delivery might someday be achieved using nanoparticle-based
systems. © 2013 Wiley Periodicals, Inc.
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THE CONCEPT OF TARGETED DRUG
DELIVERY
Targeted drug delivery has been one of themost elusive goals of medical therapy.1 Unlike
conventional molecular targeting, where there is
a unique biological activity that is the focus of
the therapeutic, targeted drug delivery involves the
concept that a drug can be delivered to a specific cell
or cell type.2 In this case, a therapeutic can have a
desired effect but targeting minimizes the side effects
often associated with entry into nontargeted normal
cells. Targeting can provide remarkable improvements
in the therapeutic index of an agent (Figure 1), which
can allow drugs with excess toxicity to be used
safely and effectively.3 In addition, it can improve
the desired effect of an agent by delivering higher
concentrations of a molecule to the targeted cell,
potentially overcoming resistance to a therapeutic.4
While targeted drug delivery has been predominantly
associated with cancer chemotherapy, where the side
effects of cytotoxic drugs are devastating, it also offers
opportunities for the treatment of cardiovascular,
metabolic, and inflammatory diseases where higher
doses of potentially useful therapies are required than
can be safely used in human applications.5 However,
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numerous technical limitations have prevented the
development of most applications of targeted drug
delivery.6 To understand these limitations, it is
important to examine the functional requirements
for the targeted therapeutics; this will also provide




Conventional therapeutics are typically small molecule
drugs (MW < 1000 Da). Once injected or absorbed
from the gastrointestinal tract these molecules can
easily diffuse through vascular pores, escaping the
bloodstream, and dispersing through the tissue matrix
to reach cells.7 These molecules can then pass
across the cell membrane into the interior and the
nucleus of the cell where they have their action.
In contrast, targeted therapeutics utilize a delivery
system based on carrier macromolecules that are
orders of magnitude larger in size (Figure 2). Most
targeted therapeutics have two molecules coupled to
a carrier; one chemical entity responsible for targeting
and another being the therapeutic.8 In addition,
a companion diagnostic imaging agent to identify
the presence of the target uses the same targeting
platform with an imaging molecule, again requiring
two molecules. In both cases, these small molecules
are linked to the macromolecular backbone that often
is too large to escape the vasculature or traverse
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FIGURE 1 | The ability of targeted drug therapy to reduce drug
toxicity. Mice on left dosed with free methotrexate lose weight, hair and
appear sick due to systemic toxicity. Mice on right dosed with
folate-targeted dendrimer methotrexate exhibit no adverse effects from
the chemotherapy but have drug-induced necrosis of the tumor on the
mice.
the tissue space. While there is some debate about
whether molecules like liposomes can escape the
vasculature9 a real key is the nature of the vasculature
targeted. Tumor vasculature in animals is ‘leaky’ and
this has allowed larger molecules to escape and be
retained in tumors. This has allowed for tumor therapy
based on ‘enhanced permeability and retention’ (EPR)
where carrier bound drug accumulates in tumors.
In contrast, drug carriers that can escape normal
vascular pores are probably about the same size
as the largest of proteins (<20 nm).10 Studies have
documented that molecules >100 nm in diameter do
not effectively diffuse across normal endothelium,11
and in some cases even molecules 40 nm in diameter
are problematic unless the endothelium is traumatized
by radiation or heating.12 Thus, targeted therapeutics
for nontumor applications must still be small enough
to exit the vasculature and/or traverse the interstitial
space in order to reach a target cell. Once at a target
cell, therapeutic particles have traditionally needed to
enter a cell. If the entire targeted therapeutic carrier is
required to enter the cell, size again becomes a problem
as studies with genetic therapeutics have shown that
anything greater than 150 nm does not effectively
FIGURE 2 | The challenges of drug delivery






5) Maintain drug stability and
solubility in bodily fluids
Internalize into target cells to
deliver the therapeutic
Recognize target cells and bind
with high avidity and specificity





Diffuse out of blood vessels
(particle size < 20nm)
enter cells.13 While this can be facilitated if there is
release of the drug from the carrier (see Conclusions),
this can be technically challenging. Thus, targeted drug
delivery, particularly for noncancer applications, has
awaited the development of smaller carrier structures
to serve as the basis for complex therapeutics.
NEW OPPORTUNITIES AFFORDED
BY THE EMERGING FIELD
OF NANOSCIENCE
Nanotechnology has led to a remarkable convergence
of disparate fields to address drug delivery, including
biology, applied physics, optics, computational
analysis, and modeling, as well as materials science.
Because of this, the application of nanoscale
analytical, computational, and synthetic approaches
to understanding and manipulating complex systems
involved in drug delivery offers incredible potential
for advances in the diagnosis and treatment of human
diseases. However, despite the growing interest in
nanotechnology-based therapeutics, there are still
many questions as to why nanotechnology is crucial to
therapeutic development. Most investigators focus on
the unique aspects of the technology when discussing
nanotechnology for drug delivery. However, my
perspective is that the utility of nanotechnology in
targeted therapeutic development lies in requirements
based on the structure of biological systems. In this
regard, the need for carrier materials to be less
nanometers in diameter for targeted drug delivery
in the absence of EPR is defined by biology, not
by technology. Therefore, the ability to design and
synthesize materials in the nanoscale size range
is the key facilitating element that allows for the
development of targeted therapeutics.
Described another way, a ‘nanotherapeutic’
is a complex, multicomponent material that can be
designed and synthesized specifically to target drug,
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FIGURE 3 | A dendron where a single dye molecule is coupled to multiple targeting ligands. This can also be used to target drugs as well as dyes,
and allows for every carrier to have one drug and multiple ligands for high avidity interactions and efficient targeting.
but remains small enough to pass through the tissue
matrix from the vasculature to target cells.14 Once at
a tissue target, the therapeutic must be able to identify
and bind specifically to the targeted cell. This may
involve identifying the specific expression or unique
alterations of molecules on cell membranes, but these
changes must be able to differentiate the targeted from
normal cells. In addition, these molecules must then
enter the cell and have a biological effect. This means
carrying a drug or genetic therapeutic into a cell, but
requires that the therapeutic either be active as part
of the targeted delivery system or is released from the
carrier within the cell. This latter approach provides
another level of complexity to the function of a
targeted therapeutic. Therefore, it is obvious that a
nanotherapeutic is inherently a complex but remark-
ably small molecule that serves several functions to
yield the targeted delivery of a therapeutic.
Utilizing these advances, our interdisciplinary
team at the University of Michigan Nanotechnol-
ogy Institute for Medicine and Biological Sciences
(M-NIMBS) has developed a technical solution
that provides a scaffold and linking strategy that
allows the synthesis of multifunctional combinatory
therapeutics can be designed and built.15 The scaffold
is a dendritic polymer that is uniquely suited to
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biomedical applications and has a diameter of
only 5 nm.16,17 We use multiple linker mechanisms
to couple therapeutics to the carrier molecules,
including click chemistry and oligonucleotide bridges
(Figure 3). We have completed extensive studies
providing proof of concept18,19 and have taken devel-
opment of several nanodevices through small animal
trials. These designed multifunctional devices will
have applications as targeted imaging and diagnostic
agents for several diseases at all stages of illness.
MULTIFUNCTIONAL SINGLE
DENDRIMER NANODEVICES IN VITRO
TESTING
Over the past several years, we have made great
progress in developing dendrimer-based, multifunc-
tional therapeutics. We have produced a single
dendritic molecule that has folate for targeting,
methotrexate for sensing, and gadolinium or dye
molecules for imaging (Figure 4). This involves
coupling of these functional groups to the surface of
a generation 5 PAMAM dendrimer (MW 25,000 Da,
diameter 5 nm). Doing these conjugates has proven to
be an arduous synthetic endeavor given the multiple
chemical steps that are required. Several challenging
protect–deprotect steps are needed to produce such
a multifunctional agent. This dendrimer-based agent
was used as a testing platform to evaluate the
therapeutic capability of this type of molecule. The
studies involved with developing these molecules have
been previously and extensively described.20–24 While
this was not an entirely optimized system, the size
(5–6 nM), molecular weight (40 kDa) and solubility of
this macromolecular system have provided a material
that can be used to evaluate structural aspects of the
polymer scaffold, cell delivery, and internalization to
test concepts of nanoparticle delivery.
TARGETING CANCER
We first demonstrated the ability to use dendrimers
to target drugs to specific cells in a cancer model.25
This model involves subcutaneous tumors that express
the folate receptor on KB squamous carcinoma
cells. These cells are implanted subcutaneously in a
nude mouse and then drug is administered to see
the effect on the growth of the cancer cells. This
model does not exactly represent the physiology of
human tumors, but can be employed to measure
the relative pharmacokinetics of targeted and free
drug. We injected folate-targeted dendrimers that also












FIGURE 4 | A multifunctional dendrimer containing a targeting
molecule (folate), a drug (methotrexate), and a dye molecule




















































































































FIGURE 5 | The biodistribution of targeted versus nontargeted
tritium-labeled dendrimers. Note that the uptake in the folate receptor
positive tumor was 10-fold higher in the targeted dendrimers and
persisted over time.
through the tail vein in tumor bearing mice and
were able to demonstrate specific uptake in the tumor
through fluorescence studies using labeled dendrimer.
In addition, there was decreased toxicity compared
to free drug and an improved therapeutic effect. The
material was not internalized into other organs with
cells that have the reduced folate carrier because at 5
nM diameter dendrimer was too large to go through
that ion channel. Despite this size, the dendrimer
therapeutic was still below the filtration threshold of
the kidney and was able to be excreted in the urine.
As a result, the therapy was not toxic and readily
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Reduced dendrimer modification steps•
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Well-defined structure, can be easily characterized
Synthetic flexibility, well-suited for combinatorial synthesis
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G5
FIGURE 6 | Coupling both drug (methotrexate) and targeting ligand (folate) to a dendrimer using a triazine linker and click chemistry offers more
efficient coupling and fixed ratios of drug and targeting ligand.
left the body if it was in internalized into the tumor.
There was a 10-fold improvement in tumor targeting
with almost 10% of the injected drug ending up in
the tumor (Figure 5). This suggested that systemically
administered nanoparticles could target tumors and
could improve the therapeutic index of drugs.
TARGETING ARTHRITIS
Recently, we have examined targeting folate receptor
expressing cells (activated macrophages) responsible
for inflammation in arthritis using the same folate
targeted nanoparticles.26 These studies documented
that the targeted nanoparticles were taken up by
activated macrophages bearing folate receptors and
suppressed inflammatory activities of these cells
more potently than free drug. There was also less
toxicity as documented by the fact that the splenic
weights of targeted drug treated animals were not
decreased. This suggested that as compared to free
drug targeted drug effects were limited to cells
in inflamed tissue expressing folate receptors were
targeted. This approach may provide better responses
to methotrexate in arthritis and overcome dose-
limiting toxicity of this drug.
REMAINING ISSUES WITH
NANOPARTICLE THERAPY
While it is clear from the above studies that
nanoparticle-targeted drugs could be very useful as
therapeutics there are potential concerns and there
are a number of issues that need to be resolved
before these molecules enter clinical trials. There is a
problem with the distribution of targeting ligands and
drug molecules on the nanoparticles. Current coupling
techniques give a broad distribution of molecules on
the nanoparticles within synthesized populations.27
The result of this is a population of drug delivery
molecules that have a range of targeting ligands and
drugs, and only a small portion of the molecules
(˜10%) actually have the desired effect. We are
currently examining click chemistry approaches and
new approaches at dendrimer synthesis to improve
the uniformity of these therapeutic populations.28
Another approach is to use coupling chemistries with
set ratios of drug and targeting molecule29 (Figure 6).
While there would still be a distribution of molecules
in the overall population, the ratios of drug to
targeting ligand would be fixed. This should improve
the uniformity and function of the therapeutics.
Another improvement may come from more uniform
dendrimers and other types of nanoparticles that
reduce the poly-dispersity of the backbone and provide
a more uniform platform to attach molecules.30
Exciting work from several groups also looks to
resolve some of the issues with the biological limita-
tions imposed on nanoparticle therapies. The need for
the therapeutic to transverse biological barriers, such
as vascular endothelium and blood brain barrier, has
recently been addressed.31 This type of approach,
where facilitated transport overcomes size limitations
imposed by simple membrane diffusion, could yield
exciting new types of therapies for some of the most
difficult to react targets such as nonvascularized
tumors or the brain. Also, new approaches to drug
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release and uptake by targeted cells may allow
delivery of drugs without requiring internalization of
the nanoparticle carrier.32,33 These types of advances
will allow for the more facile design of nanoparticle
therapeutics and even higher levels of delivered drug.
This again should increase the therapeutic index for
drugs involved in these delivery systems.
CONCLUSIONS
Nanoparticles are uniquely suited to target drugs to
cells because of the inherent size limitations placed
by biological systems. In addition, the ability to
couple multiple molecules to a single nanoparticle
in a consistent and effective manner is a necessary
requirement to create the ability to make complex
therapeutics that are consistently capable of targeting
cells. While there are still significant design and
engineering concerns, the ability to make complex
therapeutics that have diagnostic and imaging agents
coupled on the same molecule to allow monitoring of
drug therapy truly provide a unique opportunity for
improving therapeutics.
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